Please login to the form below

Not currently logged in

NewLink Genetics

This page shows the latest NewLink Genetics news and features for those working in and with pharma, biotech and healthcare.

Incyte/Merck trial failure bodes ill for IDO class

Incyte/Merck trial failure bodes ill for IDO class

but also other companies developing drugs against the target such as Bristol-Myers Squibb (BMS) and NewLink Genetics, which both have candidates in late-stage trials. ... note when describing the probability of success with the approach over the past

Latest news

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Communicating in a crisis Communicating in a crisis

    November 2014. Merck &Co buys rights to Ebola vaccine from NewLink Genetics .

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    2, 600. NewLink Genetics/Genentech. Collaboration and licence. For development of NLG919 and next generation IDO pathway inhibitors.

  • Pharma deals during October 2014 Pharma deals during October 2014

    But the classic licence deal lives on. Several classic licences were reported this month, notably NewLink Genetics and Genentech; Curetech and Medivation; Forendo and Apricus as well as Lexicon and Ipsen. ... Leading the pack, NewLink Genetics secured a

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...